| |
PFS
|
OS
|
|---|
|
Univariate analysis
|
Multivariate analysis
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
HR
|
p-value
|
HR
|
p-value
|
HR
|
p-value
|
HR
|
p-value
|
|---|
|
Age
|
|
<60
|
1
|
0.095
| | |
10.686
|
0.162
| | |
|
≥60
|
0.722 (0.492–1.059)
| | | |
(0.404–1.164)
| | | |
|
Performance status
|
|
ECOG < 2
|
1
|
0.059
|
1
|
0.819
|
1
|
0.002
|
1
|
0.565
|
|
ECOG ≥2
|
3.067 (0.957–9.836)
| |
1.160 (0.325–4.132)
| |
6.750 (2.068–22.026)
| |
1.494 (0.381–5.858)
| |
|
Subtypes
|
|
Mucosal
|
1
|
0.375
| | |
1
|
0.503
|
–
| |
|
Cutaneous
|
1.182 (0.687–2.033)
|
0.400
| | |
0.954 (0.503–1.810)
|
0.885
| | |
|
Acral
|
1.221 (0.767–1.944)
|
0.545
| | |
1.130 (0.548–2.329)
|
0.741
| | |
|
Uveal
|
2.506 (0.877–7.157)
|
0.086
| | |
2.407 (0.703–8.243)
|
0.162
| | |
|
Subtypes
|
|
Non-cutaneous
|
11.233
|
0.329
|
–
|
–
|
11.045
|
0.879
|
–
|
–
|
|
Cutaneous
|
(0.810–1.879)
| | | |
(0.591–1.848)
| | | |
|
M stage
|
|
M1a
|
1
|
<0.001
|
1
|
0.001
|
1
|
<0.001
|
1
|
0.017
|
|
M1b
|
1.751 (1.002–3.060)
|
0.049
|
2.032 (1.133–3.642)
|
0.017
|
1.830 (0.756–4.430)
|
0.180
|
1.769 (0.590–5.307)
|
0.309
|
|
M1c
|
2.524 (1.466–4.344)
|
0.001
|
2.257 (1.279–3.984)
|
0.005
|
4.659 (2.109–10.294)
|
<0.001
|
3.945 (1.075–14.474)
|
0.039
|
|
M1d
|
4.495 (2.073–9.747)
|
<0.001
|
5.167 (2.24–11.900)
|
< 0.001
|
5.753 (2.142–15.451)
|
0.001
|
8.838 (2.192–35.626)
|
0.002
|
|
Bone metastasis
|
|
No
|
1
|
0.005
|
1
|
0.280
|
1
|
0.011
|
1
|
0.108
|
|
Yes
|
1.959 (1.219–3.149)
| |
1.370 (0.775–2.422)
| |
2.154 (1.190–3.898)
| |
1.995 (0.860–4.629)
| |
|
Liver metastasis
|
|
No
|
1
|
<0.001
|
1
|
0.644
|
1
|
<0.001
|
1
|
0.695
|
|
Yes
|
2.228 (1.452–3.420)
| |
0.835 (0.389–1.795)
| |
3.687 (2.177–6.247)
| |
0.795 (0.253–2.502)
| |
|
BRAFV600 status
|
|
Wildtype
|
1
|
0.431
|
–
|
–
|
1
|
0.018
|
1
|
0.101
|
|
Mutant
|
1.242 (0.724–2.133)
| | | |
2.232 (1.150–4.330)
| |
2.014 (0.872–4.655)
| |
|
KIT status
|
|
Wildtype
|
1
|
0.888
|
–
|
–
|
1
|
0.333
|
–
|
–
|
|
Mutant
|
1.052 (0.519–2.131)
| | | |
1.557 (0.635–3.818)
| | | |
|
LDH
|
|
Normal
|
1
|
0.001
|
1
|
0.035
|
1
|
<0.001
|
1
|
0.011
|
|
Elevated
|
2.149 (1.361–3.393)
| |
1.723 (1.039–2.860)
| |
4.476 (2.512–7.974)
| |
2.676 (1.248–5.736)
| |
|
NLR
|
|
< 2.10
|
1
|
0.017
|
1
|
0.009
|
1
|
<0.001
|
1
|
<0.001
|
|
≥ 2.10
|
1.606 (1.090–2.367)
| |
1.802 (1.160–2.799)
| |
4.103 (2.243–7.504)
| |
4.583 (2.121–9.907)
| |
- PFS progression-free survival, OS overall survival, NRL neutrophil/lymphocyte ratio, LDH lactate dehydrogenase concentration
- The numbers in boldface represented the values with statistical significance
